X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (277) 277
animals (195) 195
mice (170) 170
humans (165) 165
human necessities (137) 137
hygiene (137) 137
medical or veterinary science (137) 137
preparations for medical, dental, or toilet purposes (135) 135
oncology (118) 118
chemistry (117) 117
metallurgy (117) 117
immunology (110) 110
microbiology (104) 104
peptides (104) 104
biochemistry (102) 102
beer (98) 98
enzymology (98) 98
mutation or genetic engineering (98) 98
spirits (98) 98
vinegar (98) 98
wine (98) 98
organic chemistry (96) 96
compositions thereof (92) 92
culture media (92) 92
microorganisms or enzymes (92) 92
propagating, preserving or maintaining microorganisms (92) 92
article (91) 91
immunotherapy (85) 85
female (77) 77
cancer (76) 76
specific therapeutic activity of chemical compounds ormedicinal preparations (76) 76
mice, inbred c57bl (69) 69
mice, inbred balb c (55) 55
male (52) 52
expression (50) 50
medicine, research & experimental (50) 50
dendritic cells (44) 44
in-vivo (42) 42
research (42) 42
t-lymphocytes - immunology (42) 42
abridged index medicus (41) 41
neoplasms - immunology (41) 41
tumors (41) 41
lymphocytes (38) 38
cell biology (37) 37
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (37) 37
physics (37) 37
investigating or analysing materials by determining theirchemical or physical properties (36) 36
measuring (36) 36
t cells (36) 36
testing (36) 36
t-cells (34) 34
activation (33) 33
melanoma (33) 33
tumor cells, cultured (33) 33
antitumor immunity (32) 32
cd8-positive t-lymphocytes - immunology (32) 32
mice, transgenic (30) 30
antigen (29) 29
cell line, tumor (29) 29
neoplasms - therapy (28) 28
flow cytometry (27) 27
immunity (27) 27
pd-1 (27) 27
antigens (26) 26
immune response (26) 26
biochemistry & molecular biology (25) 25
agriculture (24) 24
animal husbandry (24) 24
antigens, neoplasm - immunology (24) 24
care of birds, fishes, insects (24) 24
fishing (24) 24
forestry (24) 24
gene expression (24) 24
hunting (24) 24
new breeds of animals (24) 24
rearing or breeding animals, not otherwise provided for (24) 24
t-lymphocyte subsets - immunology (24) 24
trapping (24) 24
cancer vaccines - immunology (23) 23
cd4-positive t-lymphocytes - immunology (23) 23
dendritic cells - immunology (23) 23
health aspects (23) 23
regulatory t-cells (23) 23
multidisciplinary sciences (22) 22
vaccination (22) 22
adult (21) 21
care and treatment (21) 21
genetic aspects (21) 21
immune system (21) 21
middle aged (21) 21
signal transduction (21) 21
t-lymphocytes, cytotoxic - immunology (21) 21
transfection (21) 21
cells (20) 20
chemical and pharmacologic phenomena (20) 20
ligands (20) 20
mice, knockout (20) 20
b7 family (19) 19
biocides, e.g. as disinfectants, as pesticides, as herbicides (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (592) 592
French (20) 20
German (14) 14
Chinese (6) 6
Japanese (4) 4
Korean (4) 4
Portuguese (3) 3
Spanish (2) 2
Greek (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 7_suppl, pp. 210 - 210
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2509 - 2520
Persons with mismatch repair–deficient tumors are more likely than persons with mismatch repair–proficient tumors to benefit from pembrolizumab — which... 
MEDICINE, GENERAL & INTERNAL | COLORECTAL CARCINOMAS | ANTI-PD-L1 ANTIBODY | SAFETY | MICROSATELLITE INSTABILITY | DNA | GERMLINE MUTATIONS | PREDISPOSE | CLINICAL ACTIVITY | CANCER | LYMPHOCYTES | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Neoplasm Metastasis - genetics | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | DNA Mismatch Repair | Adult | Female | Adenocarcinoma - genetics | Aged | Colorectal Neoplasms - pathology | Antibody diversity | Carcinoma | Genetic disorders | Analysis | Research | Risk factors | Cancer | Tumors | Antigens | Yeast | PD-1 protein | Colorectal carcinoma | Body weight | Colorectal cancer | Autoantigens | DNA repair | Survival | Metastases | Pembrolizumab | Immune checkpoint | Immunogenicity | Mismatch repair | Death | Mutation | Genetic recombination | Cancer therapies | Drug dosages | Immune system | Medical research | Melanoma | Patients | Studies | Hypotheses | Pancreatic cancer | Epigenetics | Biomarkers | Ligands | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2542 - 2552
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2014, Volume 111, Issue 51, pp. 18321 - 18326
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 5/2016, Volume 128, Issue 1, pp. 183 - 183
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s11060-016-2130-0 
Medicine & Public Health | Neurology | Oncology | Medical colleges | Biomedical engineering
Journal Article
Science, ISSN 0036-8075, 07/2017, Volume 357, Issue 6349, pp. 409 - 413
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed... 
CELL LUNG-CANCER | SURVIVAL | COLORECTAL CARCINOMAS | RECEIVING NIVOLUMAB | IMMUNOTHERAPY | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | NEOANTIGENS | CHECKPOINT BLOCKADE | LYMPHOCYTES | Neoplastic Syndromes, Hereditary - immunology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplastic Syndromes, Hereditary - mortality | Young Adult | Colorectal Neoplasms - therapy | Brain Neoplasms - immunology | DNA Mismatch Repair | Aged, 80 and over | Adult | Female | Neoplastic Syndromes, Hereditary - genetics | Brain Neoplasms - mortality | Biomarkers, Tumor - antagonists & inhibitors | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm - immunology | Brain Neoplasms - genetics | Disease-Free Survival | Colorectal Neoplasms - immunology | Cell Cycle Checkpoints - drug effects | Brain Neoplasms - therapy | Neoplastic Syndromes, Hereditary - therapy | T-Lymphocytes - immunology | Aged | Mutation | Programmed Cell Death 1 Receptor - immunology | Colorectal cancer | Genetic aspects | Nucleotide sequencing | Health aspects | DNA repair | Methods | Tumors | DNA sequencing | Yeast | PD-1 protein | Antibodies | Clinical trials | Genomes | Functional analysis | Lymphocytes T | Patients | Survival | Colon cancer | Immune checkpoint | Immunotherapy | Mismatch repair | Pancreatic cancer | Biomarkers | Bioindicators | Colon | Solid tumors | Genetic recombination | Repair | Cancer | Apoptosis | Index Medicus
Journal Article